The Protocol Review and Monitoring System (PRMS) provides essential support for the research mission of the FHCRC/UW Cancer Consortium in conducting clinical research. Results of this research help to define the best ways to prevent cancer and to treat and care for those affected by cancer. PRMS activities help ensure that efforts focus on protocols of the highest quality and most innovative character. These activities also help ensure that cancer patients served by the Consortium have opportunities to participate in studies matching the types and stages of diseases that occur in this population. The PRMS ensures that cancer- relevant human research is scientifically important, has a sound biostatistical foundation and supports the research mission of the Consortium. The PRMS also ensures that research is designed appropriately without excluding special populations for non-scientific reasons and is feasible, with reasonably attainable accrual targets given the available patient population. The Scientific Review Committee (SRC) has the primary role in the PRMS. Members of the SRC have deep, multidisciplinary expertise, including medical oncology, surgical oncology, radiation therapy, pediatrics, nursing, pathology, laboratory sciences, cancer imaging, pharmacy and biostatistics. Portfolios of research protocols are organized and maintained by defined Research Groups, each led by a senior faculty member. The SRC conducts an independent review of all new protocols and has well-defined approval criteria designed to ensure that goals of the PRMS are met. The SRC also reviews accrual and scientific progress for each study at 6-month intervals in order to ensure efficient use of resources, using well-defined approval criteria for continued accrual. Allowances are made for trials that focus on a rare disease or condition, those that are narrowly targeted, for investigator- initiated trials that have outstanding scientific merit, and for multi-site trials that are making adequate overall progress even if enrollment at the Consortium is low. The PRMS complements, but does not overlap with the functions or role of the IRB, which functions independently and is focused on human subjects protection.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-44
Application #
9617720
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Barault, Ludovic; Amatu, Alessio; Siravegna, Giulia et al. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67:1995-2005
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Molina, Yamile; Briant, Katherine J; Sanchez, Janeth I et al. (2018) Knowledge and social engagement change in intention to be screened for colorectal cancer. Ethn Health 23:461-479
Winters, Brian R; Vakar-Lopez, Funda; Brown, Lisha et al. (2018) Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol Oncol 36:342.e7-342.e14
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Baker, K Scott; Syrjala, Karen L (2018) Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program 2018:146-153
Miller, Chris P; Tsuchida, Connor; Zheng, Ying et al. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:610-620
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655

Showing the most recent 10 out of 1267 publications